Novartis stops mid‑stage Fabhalta trial for lupus nephritis
Novartis announced on Oct. 15‑16, 2026 that it is terminating the Phase 2 study of Fabhalta, an oral Factor B inhibitor, aimed at treating lupus‑related kidney disease. The company said the move reflects strategic considerations rather than safety or efficacy concerns. The decision was reported by several news outlets on Oct. 16, 2026.
Why it matters
The halt removes a potential future revenue source from Novartis' immunology pipeline, which may affect analysts' growth forecasts for the company. Dividend‑focused investors may still view the stock as attractive because the company’s dividend yield and payout ratio remain unchanged, according to GuruFocus data.
Key facts
- 1Novartis announced the termination of the mid‑stage Fabhalta trial on Oct. 16, 2026. marketscreener.com
- 2Fabhalta is an oral Factor B inhibitor that was being evaluated for lupus nephritis. tokenpost.com
- 3Novartis cited “strategic considerations” as the reason for stopping the trial. gurufocus.com
- 4The trial was a Phase 2 (mid‑stage) study. tokenpost.com
- 5Novartis’ dividend yield is 3.15% with a payout ratio of 43% and a three‑year dividend growth rate of 5%, according to GuruFocus. gurufocus.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.